Genetic Barriers to Resistance and Impact on Clinical Response

Table 2 Incidence of the Emergence of Mutations During Therapy at the First Failure Timepoint in the SOLO Study[37]

	FPV/r Once Daily	NFV Twice Daily	P Value
No resistance mutations	84%	31%	<.001
Primary or secondary PI mutations	0%	50%	<.001
M184I/V	13%	69%	<.001
K65R, L74V	0%	6%	.784

Adapted with permission from MacManus et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651–655.